Abstract: Vehicles may have autonomous capabilities that permit the vehicle to navigate according to varying levels of participation by a human operator. A human operator may be associated with a driving capability profile and the environment surrounding a vehicle may be associated with an environmental risk profile. A vehicle, or another party in communication with a vehicle, may determine whether, based on the human operator's driving capability profile and the environmental risk profile, it is likely that the vehicle will be navigated more safely if there is a change to the vehicle's autonomous capabilities and a corresponding change to the human operator's driving responsibilities. If it is determined that a change in autonomous vehicle capability is likely to increase safe navigation of the vehicle, an insurer may offer an insurance premium cost reduction if the human operator agrees to the proposed change in autonomous capabilities.

Abstract: A display may have a pixel array such as a liquid crystal pixel array. The pixel array may be illuminated with backlight illumination from a direct-lit backlight unit. The backlight unit may include an array of light-emitting diodes (LEDs) on a printed circuit board. The display may have a notch to accommodate an input-output component. Reflective layers may be included in the notch. The backlight may include a color conversion layer with a property that varies as a function of position. The light-emitting diodes may be covered by a slab of encapsulant with recesses in an upper surface.

Abstract: A method includes determining a fuel amount; providing navigation directions; determining a vehicle arrival; transmitting a fuel purchase request; controlling a tank cover; receiving fuel; detecting that a tank is full; and transmitting a stop fueling request. A computer system includes a processor configured to: determine a fuel amount; provide navigation directions; determine a vehicle arrival; transmit a fuel purchase request; cause a pump to provide fuel; control a tank cover; detect that a tank is full; and transmit a stop fueling request. A non-transitory computer-readable medium storing thereon a set of instructions that, when executed on a processor, causes the processor to: determine a fuel amount; provide navigation directions; determine a vehicle arrival; transmit a fuel purchase request; cause a pump to provide fuel; control a tank cover; detect that fuel tank is full; and transmit a stop fueling request.

Abstract: Aqueous formulations of indacaterol are disclosed. The formulations may find use in the treatment of respiratory disorders, inflammatory disorders, or obstructive airway diseases. Methods of using the formulations and kits comprising the formulations are also encompassed by the disclosure.

Abstract: In a computer-implemented method, alert responsiveness data indicating how responsive a driver is to one or more types of vehicle alerts is received. The method also includes generating or modifying a driver profile associated with the driver, the driver profile including alert responsiveness profile information based upon the alert responsiveness data, and identifying, based at least upon the generated or modified driver profile, a suggested vehicle type. Identifying the suggested vehicle type includes determining that the generated or modified driver profile meets a set of one or more matching criteria associated with the suggested vehicle type at least in part by determining that the alert responsiveness profile information meets one or more criteria indicative of reliability of the suggested vehicle type. The method also includes causing an indication of the suggested vehicle type to be displayed to a user.

Abstract: Devices, systems, and methods for real-time peeling are disclosed. Peeling can include including evaluating and controlling one or more peelers to remove peel from organic materials. Evaluation can be performed by an evaluation system including a convolutional neural network to determine a peel value. Control can be performed by a machine learning model on the basis of the peel value. Control can include determination of real-time settings for peeler tool speed and/or gate position.

Abstract: An autoinjector is described that includes an outer body, a first trigger, an output needle, and a first compartment. The first compartment is positioned within the outer body and includes (i) a main body, (ii) a first biasing member coupled to the first trigger, and (iii) a protrusion positioned at a distal end of the main body. The autoinjector further includes a second compartment positioned in the outer body and in fluid communication with the first compartment and the output needle. The autoinjector also includes a second biasing member coupled to a second trigger. The first biasing member is configured to, upon application of force to the first trigger, automatically move an ampule in a distal direction relative to the main body to force the ampule against the protrusion, so as to break the ampule and allow a medicament to flow from the ampule to the second compartment.

Abstract: The present invention discloses pharmaceutical-grade ferric organic compounds having enhanced dissolution rate. These ferric organic compounds, including but are not limited to ferric citrate, are useful for treating chronic kidney disease.

Abstract: The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.

Abstract: Devices, systems, and methods for real-time peeling are disclosed. Peeling can include including evaluating and controlling one or more peelers to remove peel from organic materials. Evaluation can be performed by an evaluation system including a convolutional neural network to determine a peel value. Control can be performed by a machine learning model on the basis of the peel value. Control can include determination of real-time settings for peeler tool speed and/or gate position.

Abstract: The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.

Abstract: Provided are a computer program product, system, and method for generating and deploying code files compiled on build machines. Source code is maintained at a deployment system. Commands are sent to build machines to compile the source code into object code. The build machines have different operating systems to compile the object code. The deployment system stores the object code for each build machine in an object code file directory to provide executable object code for an operating system installed at the build machine. Different object code file directories are maintained for the object code compiled by the build machines having different operating systems. Access is provided to the object code in the object code file directories to run-time machines. Each run-time machine accesses the object code file directory in the deployment system having the object code compiled for an operating system version deployed on the run-time machine.

Abstract: The present invention discloses pharmaceutical-grade ferric organic compounds having enhanced dissolution rate. These ferric organic compounds, including but are not limited to ferric citrate, are useful for treating chronic kidney disease.

Abstract: Provided are a computer program product, system, and method for generating and deploying code files compiled on build machines. Source code is maintained at a deployment system. Commands are sent to build machines to compile the source code into object code. The build machines have different operating systems to compile the object code. The deployment system stores the object code for each build machine in an object code file directory to provide executable object code for an operating system installed at the build machine. Different object code file directories are maintained for the object code compiled by the build machines having different operating systems. Access is provided to the object code in the object code file directories to run-time machines. Each run-time machine accesses the object code file directory in the deployment system having the object code compiled for an operating system version deployed on the run-time machine.

Abstract: An autoinjector is described that includes an outer body, a first trigger, an output needle, and a first compartment. The first compartment is positioned within the outer body and includes (i) a main body, (ii) a first biasing member coupled to the first trigger, and (iii) a protrusion positioned at a distal end of the main body. The autoinjector further includes a second compartment positioned in the outer body and in fluid communication with the first compartment and the output needle. The autoinjector also includes a second biasing member coupled to a second trigger. The first biasing member is configured to, upon application of force to the first trigger, automatically move an ampule in a distal direction relative to the main body to force the ampule against the protrusion, so as to break the ampule and allow a medicament to flow from the ampule to the second compartment.

Abstract: An autoinjector is described that includes an outer body, a first trigger, an output needle, and a first compartment. The first compartment is positioned within the outer body and includes (i) a main body, (ii) a first biasing member coupled to the first trigger, and (iii) a protrusion positioned at a distal end of the main body. The autoinjector further includes a second compartment positioned in the outer body and in fluid communication with the first compartment and the output needle. The autoinjector also includes a second biasing member coupled to a second trigger. The first biasing member is configured to, upon application of force to the first trigger, automatically move an ampule in a distal direction relative to the main body to force the ampule against the protrusion, so as to break the ampule and allow a medicament to flow from the ampule to the second compartment.

Abstract: The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.

Abstract: The present invention provides methods of treating soft tissue calcification in a subject, comprising a step of administering to said subject an effective amount of ferric organic compound, such as ferric citrate. The claimed methods may prevent, reverse, delay or stabilize soft tissue calcification in a subject having chronic kidney disease. Affected soft tissue calcification includes soft tissue calcification in the joint, skin, eye, in cardiovascular system such as heart valve, myocardium, coronary arteries and arteriole, or in internal organs such as kidney and lung.

Abstract: The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.

Abstract: The present invention discloses pharmaceutical-grade ferric organic compounds having enhanced dissolution rate. These ferric organic compounds, including but are not limited to ferric citrate, are useful for treating chronic kidney disease.